Machine learning predicts survival for colorectal cancer patients

Date:

Colorectal cancer (CRC) is one of the most common types of cancer, with an estimated 1.8 million new cases annually. In Brazil, around 41 thousand new cases of CRC are estimated between 2020 and 2022, making it a prime opportunity for mortality and survival prediction studies. A recent study sought to evaluate and compare the accuracy of three machine learning algorithms in predicting CRC patient survival in São Paulo, Brazil, based on data from the Hospital Based Cancer Registries of São Paulo state (RHC-SP). After analyzing data from over 31,000 patients, the study found that both Random Forest and XGBoost models provided better performance than neural networks and Naive Bayes models. The top five most important features that influenced patient survival included clinical staging, year of diagnosis, presence of recurrence, surgery, and age.

The company or organization behind the study is not mentioned in the article.

The person(s) behind the study are also not mentioned in the article.

See also  Revolutionizing Blood Pressure Monitoring: Wearable Tech Breakthrough

Frequently Asked Questions (FAQs) Related to the Above News

Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.

Share post:

Subscribe

Popular

More like this
Related

Obama’s Techno-Optimism Shifts as Democrats Navigate Changing Tech Landscape

Explore the evolution of tech policy from Obama's optimism to Harris's vision at the Democratic National Convention. What's next for Democrats in tech?

Tech Evolution: From Obama’s Optimism to Harris’s Vision

Explore the evolution of tech policy from Obama's optimism to Harris's vision at the Democratic National Convention. What's next for Democrats in tech?

Tonix Pharmaceuticals TNXP Shares Fall 14.61% After Q2 Earnings Report

Tonix Pharmaceuticals TNXP shares decline 14.61% post-Q2 earnings report. Evaluate investment strategy based on company updates and market dynamics.

The Future of Good Jobs: Why College Degrees are Essential through 2031

Discover the future of good jobs through 2031 and why college degrees are essential. Learn more about job projections and AI's influence.